阿卡波糖联合沙格列汀治疗二甲双胍血糖控制不佳2型糖尿病的临床研究

Clinical Study of Acarbose Combined with Sagliptin in the Treatment of Type 2 Diabetes Mellitus with Poor Glycemic Control of Metformin

目的探讨阿卡波糖联合沙格列汀对二甲双胍血糖控制不佳2型糖尿病的临床应用效果。方法选取2017年1月-2018年1月暨南大学附属顺德医院收治的二甲双胍血糖控制不佳的2型糖尿病患者88例,按照随机数字表法分为2组,对照组(44例)和观察组(44例)。对照组患者采用沙格列汀进行治疗,观察组患者在对照组治疗基础上联合阿卡波糖进行治疗,观察分析两组患者的糖化血红蛋白(HbA1c)、空腹血糖(FBG)、餐后2 h血糖(PG2h)、血糖下降的幅度及其安全性。结果治疗后,观察组HbA1c、FBG、PG2h水平较对照组低,差异有统计学意义(P<0.05)。对照组的血糖下降幅度为(2.39±0.42)mmol/L,观察组的血糖下降幅度为(4.23±0.51)mmol/L,对照组的血糖下降幅度较观察组低,差异有统计学意义(t=18.474,P=0.000)。观察组用药安全性较对照组高,差异有统计学意义(P<0.05)。结论二甲双胍血糖控制不佳的2型糖尿病通过沙格列汀联合阿卡波糖治疗,可有效控制血糖水平,且不良反应现象较少,安全性高。

Objective To investigate the clinical effect of acarbose combined with sagliptin on type 2 diabetes mellitus with poor glycemic control of metformin. Methods 88 patients with type 2 diabetes mellitus who were admitted to the hospital from January,2017 to January,2018 were randomly divided into two groups,it control group(44 cases) and observation group(44 cases). The patients in the control group were treated with sagliptin,while those in the observation group were treated with acarbose on the basis of the treatment in the control group. The glycosylated hemoglobin(HbA1 c),fasting blood glucose(FBG),postprandial blood glucose(PG2 h),the extent of blood glucose decline and their safety were observed and analyzed. Results After treatment, the levels of HbA1 c,FBG and PG2 h in the observation group were lower than those in the control group(P<0.05).The decrease of blood glucose in the control group was(2.39±0.42) mmol/L,that in the observation group was(4.23 ± 0.51)mmol/L,and that in the control group was lower than that in the observation group(t=18.474,P=0.000). The medication safety of the observation group was higher than that of the control group,and the difference was statistically significant(P<0.05).Conclusion Metformin combined with acarbose can effectively control the level of blood sugar in type 2 diabetes mellitus with less adverse reactions and high safety.